This randomized, double-blind, sham-controlled trial was conducted at Bijan Center for Substance Abuse Treatment in Tehran, Iran. The data were collected from December 2015 to June 2016.
The inclusion criteria were (1) age of 18 - 65 years, (2) ongoing patient status at the addiction clinic, (3) methadone intake for at least two years (syrup, mean ± SD = 35 ± 0.3 cc/per day), (4) screening based on scores within two standard deviations on the suicidal ideation scale of Beck and the diagnosis of persistent depressive disorder (dysthymia) based on diagnostic interviews and the adoption of DSM-5 criteria (since the minimum period for avoiding opioids other than methadone was considered two years, dysthymia symptoms after complete abstinence are short-term and are different from the diagnosis of mood disorders without a history of substance use), and (5) the history of at least one episode of suicide planning or committing.
The exclusion criteria included (1) nickel-allergy, (2) ear infection, (3) heart disease, (4) taking any psychiatric medication, and (5) receiving psychological interventions within the three months leading up to the study. In this study, concerning the one-way direction test and the assumptions of Z = 1.645, d = 0.2, α = 0.05, and the test power of 1 - β = 0.84, the sample size was estimated at 24 people. The sample was selected through respondent-driven sampling (RDS). The randomization sequence was computer-generated, with the randomization itself conducting using SPSS 20 software (random number generation) (SPSS, Inc., Chicago, IL, USA). The statistical significance was accepted at the level of P < 0.05. The allocation concealment was done by the researcher who was responsible for the randomization.
Acupuncture was performed twice a week for four weeks (eight sessions) in both ears using disposable stainless steel needles (0.25 + 13 mm) with a depth of 2 - 3 mm and using manual stimulation. Participants in the sham group also received eight sessions of acupuncture treatment; however, needling was performed 1 cm away from the real acupoints.
Cortisol was evaluated in the form of three meals on a randomly selected day every week and the mean of the three measures was considered as a criterion. Cortisol was collected from the saliva into labeled tubes. The patients were taught about eating, brushing the teeth, or any drink (except water) in hours prior to the testing session. The cortisol samples were stored at ≤ -20ºC and analyzed by enzyme-linked immunosorbent assay kit (ELISA).
Data collection was conducted using structured clinical interviews, a researcher-made demographic questionnaire, the suicide scale, and the radioimmunoassay method. The structured clinical interview for DSM-5 (SCID) was used for the diagnosis of dysthymia disorder based on DSM-5. A researcher-made demographic questionnaire was used by the researcher to collect personal information. The Beck scale for suicidal ideation (BSSI) is a 21-item scale to assess the severity of ideation and planning to commit suicide during the past seven days. Cronbach’s alpha of this scale was calculated in the range of 0.81 to 0.91. The validity of the Persian version of this scale was estimated at 0.95 (
14). Radioimmunoassay (RIA) is a tool widely used at medical laboratories. In this method, radioactive iodine is used to create signals. Urinalysis was performed to ensure that the patients adhered to the maintenance treatment. A urine test with the threshold of > 300 ng/mL was done for each participant weekly and randomly (
3).
According to the results of the Kolmogorov-Smirnov test related to the non-normal distribution of the two variables, the generalized estimation equation test was used. The chi-square test was used to evaluate the demographic characteristics.
After completing the explanation of the study details, written informed consent was obtained from eligible patients in their native language (Persian). Patients received only treatment routine- centered treatment. All stages of the study were performed after obtaining informed consent from patients and based on the latest version of the Helsinki Declaration. This trial was registered at www.clinicaltrials.in.th (TCTR20180328001, ethical approval: IR.SBMU.RETECH.REC.1397.631).